New Wave Biotech
Category: AI in Analytics & BI
New Wave Biotech develops AI-driven downstream process optimization software designed to accelerate the market entry of synthetic biology (SynBio) products. New Wave Biotech was founded in 2022. The company is led by Zoe Yu Tung Law. Based in Manchester, United Kingdom. Team size: 2-10. Total funding raised: N/A. Latest round: Grant round on October 21, 2024. Key investors include EIT Food, Big Idea Ventures, Innovate UK.
- Founded
- 2022
- Headquarters
- Manchester, United Kingdom
- Team size
- 2-10
- Total funding
- N/A
Value proposition
Accelerating R&D and reducing production costs for SynBio products through AI-driven process optimization.
Products and solutions
Bioprocess Foresight software
Unique value
AI-driven downstream process optimization for SynBio products
Target customer
SynBio innovators working on alternative proteins, biochemicals, and biomaterials
Industries served
Biotechnology, Synthetic Biology
Technology advantage
Enables faster and more cost-effective market entry for SynBio products
How they differentiate
Focus on AI-driven process optimization for SynBio products
Main competitors
Invert, Neuranics, BioReact
Key partnerships
Multus
Major milestones
Secured €1.2M funding to advance AI-powered bioprocess simulation technology
Growth metrics
Not specified
Market positioning
Emerging player in the SynBio process optimization space
Geographic focus
Global
Patents and IP
Not specified
About Zoe Yu Tung Law
Zoe Yu Tung Law is the Co-founder and CEO of New Wave Biotech. She has experience in business development and has been leading the company since its inception in 2022.
Official website: https://www.newwavebiotech.com